Developments in herpes simplex virus vaccines: old problems and new challenges.

摘要: Vaccination has remained the best method for preventing virus spread. The herpes simplex (HSV) candidate vaccines tested till now were mostly purified subunit and/or recombinant envelope glycoproteins (such as gB and gD). In many experiments performed in mice, guinea pigs rabbits, clear-cut protection against acute challenge was demonstrated along with reduction of extent latency, when established immunized host. immunotherapeutic effect seems less convincing. However, introduction new adjuvants, which shift cytokine production helper T-cells toward stimulation cytotoxic (TH1 type response), reveals a promising development. Mathematical analysis proved that overall prophylactic vaccination seronegative women, even eliciting 40–60 % antibody response only, would reduce frequency genital within vaccinated population. Even partially effective, might represent suitable alternative chronic chemotherapy recurrent labial herpes.